Nephrotic Syndrome (NS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Nephrotic Syndrome (NS) Market Outlook

Thelansis’s “Nephrotic Syndrome (NS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Nephrotic syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Nephrotic Syndrome (NS) Overview

Nephrotic syndrome (NS) is characterized by significant proteinuria (exceeding 40 mg/m^2 per hour), leading to hypoalbuminemia (less than 30 g/L), hyperlipidemia, edema, and various complications. It arises from increased permeability across the damaged basement membrane in the renal glomerulus. This abnormality in glomerular permeability can be primary, with kidney-specific diseases, or secondary, resulting from congenital infections, diabetes, systemic lupus erythematosus, neoplasia, or certain medications. Primary causes of NS include intrinsic kidney diseases like membranous nephropathy, minimal-change nephropathy, and focal glomerulosclerosis. Secondary causes encompass systemic diseases such as lupus erythematosus, diabetes mellitus, and amyloidosis. Congenital or hereditary focal glomerulosclerosis may result from genetic mutations affecting podocyte proteins like podocin, nephrin, or cation channel 6 protein, with minimal change in glomerulonephritis being the most prevalent cause in children. Medications can also induce nephrotic syndrome, including minimal-change disease associated with nonsteroidal anti-inflammatory drugs (NSAIDs) and membranous glomerulonephritis linked to gold, bucillamine, and penicillamine, commonly used for rheumatic diseases. NS can be classified as primary or secondary. Primary forms stem from kidney-specific disorders damaging the glomeruli, while secondary forms involve systemic conditions affecting other body parts. Common disorders causing secondary NS include diabetes mellitus, systemic lupus erythematosus (lupus), and certain viral infections.

• In the United States, 2-4 out of every 100,000 children are diagnosed with primary NS annually, with a higher incidence in males compared to females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: